Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus) (NivoPlus)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02423954
Recruitment Status : Terminated (Investigator no longer at site to enroll patients or write up data)
First Posted : April 22, 2015
Last Update Posted : July 2, 2018
Sponsor:
Information provided by (Responsible Party):
Western Regional Medical Center

Tracking Information
First Submitted Date  ICMJE April 13, 2015
First Posted Date  ICMJE April 22, 2015
Last Update Posted Date July 2, 2018
Actual Study Start Date  ICMJE April 2015
Actual Primary Completion Date November 1, 2017   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: June 23, 2017)
The recommended phase 2 dose (RP2D) of chemotherapy in combination with nivolumab in subjects with advanced cancer. [ Time Frame: up to 4 weeks ]
phase 2 dosing of nivolumab + chemotherapy
Original Primary Outcome Measures  ICMJE
 (submitted: April 21, 2015)
The recommended phase 2 dose (RP2D) of chemotherapy in combination with nivolumab in subjects with advanced cancer. [ Time Frame: up to 4 weeks ]
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: June 28, 2018)
  • Frequency of grade 3 or higher treatment-related adverse events by CTCAE 4.03 [ Time Frame: up to 12 months ]
    Identify adverse Events
  • Response rate by irRC and response evaluation criteria in solid tumors (RECIST) 1.1 criteria1,2 [ Time Frame: 12 weeks ]
    Identify tumor response
  • The overall survival (OS) and progression-free survival (PFS) [ Time Frame: up to 12 months ]
    Assess time until death after treatment
  • Quantify changes in amount of blood proteins and circulating tumor DNA in patients enrolled on this study [ Time Frame: up to 12 months ]
    Assess tumor marker levels
Original Secondary Outcome Measures  ICMJE
 (submitted: April 21, 2015)
  • Frequency of grade 3 or higher treatment-related adverse events by CTCAE 4.03 [ Time Frame: up to 12 months ]
  • Response rate by irRC and response evaluation criteria in solid tumors (RECIST) 1.1 criteria1,2 [ Time Frame: 12 weeks ]
  • The overall survival (OS) and progression-free survival (PFS) [ Time Frame: up to 12 months ]
  • Quantify changes in amount of blood proteins and circulating tumor DNA in patients enrolled on this study [ Time Frame: up to 12 months ]
  • Quantify pixel changes identified on imaging [ Time Frame: 12 weeks ]
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus)
Official Title  ICMJE A Phase Ib/II Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus)
Brief Summary Determine Phase 2 dose of study drug
Detailed Description Determine the recommended phase 2 dose (RP2D) of chemotherapy in combination with nivolumab in subjects with advanced cancer.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Phase 2
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE
  • Advanced Cancer
  • Pancreatic Cancer
  • Renal Cell Cancer
  • Non Small Cell Lung Cancer
  • Colorectal Carcinoma
  • Endometrial
  • Uterine
Intervention  ICMJE
  • Drug: Temsirolimus
    Other Name: Torisel
  • Drug: Irinotecan
    Other Name: Camptosar
  • Drug: Irinotecan + capecitabine
    Other Name: Camptosar + Xeloda
  • Drug: nivolumab
    Other Name: Opdivo
Study Arms  ICMJE
  • Experimental: Arm 1
    Temsirolimus 25 mg every 14 days + nivolumab
    Interventions:
    • Drug: Temsirolimus
    • Drug: nivolumab
  • Experimental: Arm 2
    Irinotecan 150 mg/m2 every 14 days + nivolumab
    Interventions:
    • Drug: Irinotecan
    • Drug: nivolumab
  • Experimental: Arm 3
    Irinotecan + capecitabine + nivolumab irinotecan 175 mg/m2 on day 1 every 14 days + capecitabine 1000 mg PO BID days 1-5 on, days 6-7 off, each 7 day period
    Interventions:
    • Drug: Irinotecan + capecitabine
    • Drug: nivolumab
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Terminated
Actual Enrollment  ICMJE
 (submitted: June 28, 2018)
33
Original Estimated Enrollment  ICMJE
 (submitted: April 21, 2015)
49
Actual Study Completion Date  ICMJE November 1, 2017
Actual Primary Completion Date November 1, 2017   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion criteria for Phase Ib and II:

  1. Patient at least 18 years old and has definitive histologically or cytologically confirmed metastatic solid tumor.
  2. Patient has one or more metastatic tumors measurable by CT scan (or PET/CT, if patient is allergic to CT contrast media). Tumor sites that are considered measureable must not have received prior radiation therapy. For metastatic tumors not measurable by CT and/or PET/CT, there needs to be tumor measuring at least 1cm in one dimension by digital calipers on physical exam.
  3. Patients can be enrolled only on one of the treatment arms on this trial.
  4. The investigator will select the appropriate treatment arm for the patient with the following requirements: (a) Patients cannot have had prior progression or intolerance on the single agent chemotherapy and then enrolled on an arm with that same single agent chemotherapy plus nivolumab (b) The chemotherapy on the arm selected must be considered standard of care or its components listed in the NCCN guidelines (www.nccn.org) for that cancer type.
  5. Have recovered from acute toxicities of prior treatment:

    • > 3 weeks must have elapsed since receiving any investigational agent.
    • > 2 weeks must have elapsed since receiving any radiotherapy, or ≥ 3 weeks or 5 half-lives whichever is shorter for treatment with cytotoxic or biologic agents ( ≥ 6 weeks for mitomycin or nitrosoureas). Chronic treatment with non-investigational gonadotropin-releasing hormone analogs or other hormonal or supportive care is permitted.
  6. Patient has adequate biological parameters as demonstrated by the following blood counts at time of screening:
  7. Absolute neutrophil count (ANC) > 1500 mm3, platelet count ≥ 100×109 L, hemoglobin ≥ 9 g/dL. Subject can be given packed red blood cell transfusion
  8. Calculated creatinine clearance > 40 ml/min by Cockroft-Gault equation:

    [CreatClear = Sex * ((140 - Age) / (SerumCreat)) * (Weight / 72); where Sex = 1 for men and 0.85 for women], total bilirubin 1.5 times the upper limit of normal (ULN) range, AST/ALT ≤ 3 times the upper limit of normal (ULN) range.

  9. Thyroid stimulating hormone (TSH) within institutional normal limits. If TSH is above the upper limit of normal range, then a free T4 within institutional normal limits is acceptable. If thyroid replacement therapy is initiated then patient may be screened and enrolled once the above criterion is met.
  10. Persistent prior systemic therapy non-hematologic AE grade ≤ 2 (except alopecia or correctable electrolyte abnormality with supplementation)
  11. Patient has a Karnofsky performance status (KPS) ≥ 70.
  12. Women of child-bearing potential (i.e., women who are pre-menopausal or not surgically sterile) must be willing to use an acceptable contraceptive method (abstinence, oral contraceptive or double barrier method) for the duration of the study and for 5 months following the last dose of nivolumab and 30 days following the last dose of chemotherapy on this trial on this trial, and must have a negative urine or serum pregnancy test within 2 weeks prior to beginning treatment on this trial. If a female subject or female partner of a male subject becomes pregnant during this period then patient will be recommended to seek appropriate obstetric care. The study will not be monitoring subjects or female partners of subjects for pregnancy after the last dose of study drug or chemotherapy.

Exclusion Criteria for Phase Ib and II:

  1. Active clinically serious infection > CTCAE (version 4.03) Grade 2.
  2. Serious non-healing wound, ulcer, or bone fracture.
  3. Patient has known brain metastases. Baseline imaging of the brain is required within 28 days prior to randomization.
  4. Prior therapy with a mammalian target of rapamycin (mTOR) inhibitor for the RCC subjects, prior therapy with irinotecan or topotecan for NSCLC subjects, and prior therapy with irinotecan for CRC patients.
  5. Inability to complete informed consent process and adhere to the protocol treatment plan and follow-up requirements.
  6. Patient has known active infection with HIV, hepatitis B, or hepatitis C (patients are NOT required to be tested for the presence of such viruses prior to therapy on this protocol).
  7. Requiring daily corticosteroid dose ≥ 10 mg prednisone or equivalent per day.
  8. Patient has undergone major surgery, other than diagnostic surgery (e.g., surgery done to obtain a biopsy for diagnosis without removal of an organ), within 4 weeks prior to Day 1 of treatment in this study.
  9. Patient has serious medical risk factors involving any of the major organ systems, or serious psychiatric disorders, which could compromise the patient's safety or the study data integrity.
  10. Patient will be receiving any other anti-cancer therapy during participation in this trial.
  11. Prior treatment with nivolumab is not allowed. Prior receipt of other PD-1 inhibitors or PD-L1 inhibitors is allowed.
  12. Active or prior documented autoimmune disease requiring systemic treatment within the past 2 years.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02423954
Other Study ID Numbers  ICMJE WG2015001
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE
Plan to Share IPD: Undecided
Responsible Party Western Regional Medical Center
Study Sponsor  ICMJE Western Regional Medical Center
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director: Jordan Waypa, MSN, FNP Western Regional Medical Center
Principal Investigator: Cynthia Lynch, MD Western Regional Medical Center
PRS Account Western Regional Medical Center
Verification Date June 2018

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP